Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 2025 monetary outcomes and enterprise updates. TECELRA®, their first business product within the sarcoma franchise, achieved $4.0 million in internet gross sales in Q1 2025, with the corporate offering full-year gross sales steering of $35-$45 million. Launch metrics present robust momentum with 28 Approved Therapy Facilities obtainable, 21 sufferers aphresed, and 14 doses invoiced. The corporate maintains a 100% manufacturing success fee with no payer denials. Their second product, lete-cel, is on observe for rolling BLA submission in late 2025 with anticipated approval in 2026. Monetary outcomes present Whole Liquidity of $60 million as of March 31, 2025, with Q1 income of $7.3 million. Nonetheless, the corporate reported a internet lack of $47.6 million and disclosed substantial doubt about their potential to proceed as a going concern.
Adaptimmune Therapeutics (NASDAQ: ADAP) ha comunicato i risultati finanziari del primo trimestre 2025 e aggiornamenti aziendali. TECELRA®, il loro primo prodotto commerciale nella linea sarcoma, ha registrato 4,0 milioni di dollari di vendite nette nel Q1 2025, con una previsione di vendite annue compresa tra 35 e 45 milioni di dollari. I dati di lancio mostrano un forte slancio con 28 Centri di Trattamento Autorizzati disponibili, 21 pazienti sottoposti advert afèresi e 14 dosi fatturate. L’azienda mantiene un tasso di successo produttivo del 100% senza rifiuti da parte dei pagatori. Il secondo prodotto, lete-cel, è in programma per la presentazione progressiva della BLA entro la positive del 2025, con approvazione prevista nel 2026. I risultati finanziari indicano una liquidità totale di 60 milioni di dollari al 31 marzo 2025 e un fatturato di 7,3 milioni di dollari nel primo trimestre. Tuttavia, l’azienda ha riportato una perdita netta di 47,6 milioni di dollari e ha espresso forti dubbi sulla capacità di continuare l’attività come azienda in funzionamento.
Adaptimmune Therapeutics (NASDAQ: ADAP) informó los resultados financieros del primer trimestre de 2025 y actualizaciones comerciales. TECELRA®, su primer producto comercial en la franquicia de sarcoma, alcanzó 4,0 millones de dólares en ventas netas en el primer trimestre de 2025, con una guía de ventas anuales completa de 35 a forty five millones de dólares. Las métricas de lanzamiento muestran un fuerte impulso con 28 Centros de Tratamiento Autorizados disponibles, 21 pacientes aféreseados y 14 dosis facturadas. La compañía mantiene una tasa de éxito de fabricación del 100% sin rechazos por parte de los pagadores. Su segundo producto, lete-cel, está en camino para la presentación progresiva del BLA a finales de 2025, con aprobación anticipada en 2026. Los resultados financieros muestran una liquidez complete de 60 millones de dólares al 31 de marzo de 2025 y unos ingresos del primer trimestre de 7,3 millones de dólares. Sin embargo, la compañía reportó una pérdida neta de 47,6 millones de dólares y reveló dudas sustanciales sobre su capacidad para continuar como empresa en marcha.
Adaptimmune Therapeutics(NASDAQ: ADAP)는 2025년 1분기 재무 결과 및 사업 현황을 발표했습니다. TECELRA®는 이들의 첫 번째 상업용 육종 프랜차이즈 제품으로, 2025년 1분기에 순매출 400만 달러를 기록했으며, 연간 매출 가이던스로 3,500만~4,500만 달러를 제시했습니다. 출시 지표는 28개의 인증 치료 센터, 21명의 환자 혈액 성분 채취, 14회 투여량 청구로 강한 성장세를 보이고 있습니다. 회사는 제조 성공률 100percent를 유지하며 지급 거절 사례가 없습니다. 두 번째 제품인 lete-cel은 2025년 말 BLA 순차 제출 예정이며, 2026년 승인 예상됩니다. 재무 결과는 2025년 3월 31일 기준 총 유동성 6,000만 달러, 1분기 매출 730만 달러를 나타냅니다. 그러나 회사는 순손실 4,760만 달러를 보고했으며, 계속기업으로서의 존속 가능성에 대해 상당한 의문을 제기했습니다.
Adaptimmune Therapeutics (NASDAQ: ADAP) a publié ses résultats financiers du premier trimestre 2025 ainsi que des mises à jour commerciales. TECELRA®, leur premier produit business dans la franchise sarcome, a réalisé 4,0 hundreds of thousands de {dollars} de ventes nettes au premier trimestre 2025, avec des prévisions de ventes annuelles includes entre 35 et 45 hundreds of thousands de {dollars}. Les indicateurs de lancement montrent une forte dynamique avec 28 centres de traitement autorisés, 21 sufferers aphérisés et 14 doses facturées. L’entreprise maintient un taux de réussite de fabrication de 100 % sans refus des payeurs. Leur second produit, lete-cel, est en bonne voie pour un dépôt progressif de la BLA fin 2025, avec une approbation anticipée en 2026. Les résultats financiers indiquent une liquidité totale de 60 hundreds of thousands de {dollars} au 31 mars 2025, avec un chiffre d’affaires de 7,3 hundreds of thousands de {dollars} au premier trimestre. Cependant, la société a déclaré une perte nette de 47,6 hundreds of thousands de {dollars} et a exprimé des doutes importants quant à sa capacité à poursuivre son activité.
Adaptimmune Therapeutics (NASDAQ: ADAP) meldete die Finanzergebnisse und Geschäftsupdates für das erste Quartal 2025. TECELRA®, ihr erstes kommerzielles Produkt in der Sarkom-Franchise, erzielte im ersten Quartal 2025 Nettoverkäufe von 4,0 Millionen US-Greenback, wobei das Unternehmen eine Jahresumsatzprognose von 35 bis 45 Millionen US-Greenback abgibt. Die Markteinführungskennzahlen zeigen eine starke Dynamik mit 28 autorisierten Behandlungszentren, 21 apherese-behandelten Patienten und 14 fakturierten Dosen. Das Unternehmen hält eine Herstellungsquote von 100 % ohne Ablehnungen durch Kostenträger aufrecht. Ihr zweites Produkt, lete-cel, ist auf Kurs für eine schrittweise BLA-Einreichung Ende 2025 mit erwarteter Zulassung im Jahr 2026. Die Finanzergebnisse zeigen eine Gesamtliquidität von 60 Millionen US-Greenback zum 31. März 2025 und einen Umsatz von 7,3 Millionen US-Greenback im ersten Quartal. Allerdings meldete das Unternehmen einen Nettoverlust von 47,6 Millionen US-Greenback und äußerte erhebliche Zweifel an der Fortführungsfähigkeit.
Optimistic
- Tecelra launch exhibiting robust acceleration with 14 doses invoiced YTD
- 100% manufacturing success fee and no payer denials for Tecelra
- Lete-cel met main endpoint with 42% ORR in pivotal trial
- Q1 2025 income elevated to $7.3 million from $5.7 million YoY
- R&D bills decreased to $28.9 million from $35.2 million YoY
Adverse
- Substantial doubt about firm’s potential to proceed as going concern
- Internet lack of $47.6 million in Q1 2025
- Whole Liquidity decreased to $59.6 million from $151.6 million in December 2024
- Debt principal paydown of $25 million made in Q1 2025
- SG&A bills elevated to $23.3 million from $19.7 million YoY
Insights
Adaptimmune’s Tecelra launch reveals robust acceleration with $4M Q1 gross sales and raised steering, regardless of regarding money place.
Adaptimmune’s Q1 outcomes reveal promising business traction for its not too long ago launched cell remedy Tecelra. The corporate reported $4.0 million in Q1 2025 Tecelra gross sales with an encouraging acceleration in affected person metrics. They’ve invoiced 14 sufferers year-to-date (2 in This fall 2024, 6 in Q1 2025, 8 in Q2 to this point), exhibiting clear sequential development that helps their newly established full-year steering of $35-45 million.
The remedy infrastructure continues to develop with 28 Approved Therapy Facilities now accepting referrals, approaching their goal of roughly 30 facilities by year-end. Essential operational metrics display robust execution with 100% manufacturing success fee and a 27-day turnaround time, addressing key considerations for cell therapies the place manufacturing challenges usually derail business potential. The absence of payer denials thus far additional derisks the business outlook.
Nonetheless, the corporate’s monetary place raises substantial considerations. Whole liquidity stands at simply $59.6 million as of March 31, 2025, down considerably from $151.6 million on the finish of 2024. This speedy money burn ($92 million in only one quarter) included a $25 million debt paydown however nonetheless displays excessive working bills. With quarterly losses of $47.6 million, the corporate explicitly acknowledges “substantial doubt about our potential to proceed as a going concern” – a severe warning.
The pipeline stays promising with lete-cel on observe for BLA submission in late 2025, which might greater than double their addressable sarcoma market. Nonetheless, the corporate has engaged TD Cowen to overview strategic choices, doubtless exploring partnerships or potential sale situations to deal with the vital funding hole earlier than lete-cel can attain market in 2026.
The threat/reward profile now hinges on whether or not Tecelra’s accelerating launch trajectory can appeal to strategic curiosity or financing earlier than the corporate’s dwindling money place turns into terminal.
Adaptimmune’s cell remedy platform reveals medical promise with good manufacturing success fee amid business enlargement.
Adaptimmune’s first-in-class cell remedy Tecelra is demonstrating encouraging market uptake in its early business part. The regular enhance in affected person metrics – from 2 invoiced sufferers in This fall 2024 to six in Q1 2025 and already 8 in early Q2 – alerts rising doctor adoption for this novel remedy modality in stable tumors, historically immune to immunotherapies.
From an oncology perspective, probably the most important achievement is the 100% manufacturing success fee. Cell therapies are notoriously difficult to supply persistently, notably for stable tumors, as they require complicated extraction, modification, and enlargement of every affected person’s T-cells. The 27-day common turnaround represents a clinically viable timeframe for sarcoma sufferers who usually have restricted remedy choices after failing typical approaches.
The enlargement to twenty-eight Approved Therapy Facilities (ATCs) creates an important specialty community infrastructure that addresses a elementary problem in cell remedy adoption – the necessity for specialised facilities with experience in each cell assortment (apheresis) and administration of those complicated merchandise. The dearth of payer denials signifies that the medical worth proposition is being acknowledged by insurance coverage firms, vital for affected person entry.
Trying forward, the lete-cel program represents the following technology of their sarcoma franchise, having demonstrated a 42% goal response fee together with 6 full responses in its pivotal trial. Full responses are notably significant in sarcoma, the place sturdy illness elimination is uncommon with typical therapies. The deliberate enlargement to extra sarcoma subtypes (synovial sarcoma and MRCLS) would considerably broaden the addressable affected person inhabitants.
Whereas the monetary challenges are regarding, the medical execution stays stable. The right manufacturing success fee and absence of manufacturing bottlenecks counsel the corporate has solved some of the troublesome points of cell remedy commercialization – dependable manufacturing – which gives beneficial validation of their technological platform whilst they navigate monetary constraints.
05/13/2025 – 07:30 AM
TECELRA® launch 2025 YTD metrics: 28 ATCs obtainable; 21 sufferers aphresed; and 14 doses invoiced
$4.0 million Tecelra internet gross sales in Q1 2025
Instituting 2025 Tecelra full yr gross sales steering of $35-$45 million
Lete-cel on observe to provoke rolling BLA submission late 2025; approval anticipated in 2026
Adaptimmune had Whole Liquidity1 of $60 million as of March 31, 2025; name at 8 a.m. EDT immediately
Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – Could 13, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), an organization redefining the remedy of stable tumor cancers with cell remedy, immediately reported monetary outcomes and supplied a enterprise replace for the primary quarter ended March 31, 2025.
Adrian Rawcliffe, Adaptimmune’s Chief Govt Officer: “The launch of Tecelra continues to quickly speed up, as evidenced by all launch metrics. In This fall 2024 we invoiced 2 sufferers, in Q1 2025 we invoiced 6 sufferers, and in Q2 to-date we now have invoiced 8 sufferers. The form of the pipeline of sufferers being examined and apheresed continues to help a strong acceleration of gross sales in Q2 and the second half of the yr, and we proceed to expertise 100% manufacturing success charges and no payer denials. Consequently, we at the moment are offering steering for 2025 Tecelra gross sales within the vary of $35-$45 million. I am assured within the crew’s potential to establish eligible sufferers, manufacture a personalised engineered T cell remedy and finally ship product, demonstrating that we now have constructed a profitable enterprise platform for cell therapies in stable tumors, paving the way in which for an equally profitable lete-cel launch in 2026.”
Tecelra launch momentum growing – first business product in Adaptimmune’s sarcoma franchise
- 28 Approved Therapy Facilities (ATCs) now accepting referrals
- On observe to have the total community of roughly 30 ATCs open by the tip of the yr
- Invoiced 2 sufferers in This fall 2024, 6 in Q1 2025, and eight in Q2 to-date (as of Could 9, 2025)
- Apheresed 3 sufferers in This fall 2024, 13 in Q1 2025, and eight in Q2 to-date (as of Could 9, 2025)
- 100% success fee in manufacturing thus far, with no capability constraints and a mean turnaround of 27 days
- Profitable affected person entry to Tecelra with no payer denials thus far
Lete-cel – subsequent product in Adaptimmune’s sarcoma franchise
- Pivotal trial met main endpoint with 42% ORR together with 6 full responses (CTOS 2024)
- On observe to provoke rolling BLA submission in late 2025; approval anticipated in 2026
- Lete-cel will greater than double the addressable affected person inhabitants within the sarcoma franchise
- Launch readiness actions are on observe
Company updates
- Evaluate of strategic choices with TD Cowen in progress
- Debt principal paydown of $25 million made in Q1 2025
Upcoming milestones
- Updates on Tecelra launch momentum
- Provoke rolling BLA for lete-cel to deal with synovial sarcoma and MRCLS in This fall 2025
Monetary Outcomes for the three months ended March 31, 2025
- Money / liquidity place: As of March 31, 2025, Adaptimmune had money and money equivalents of $41.1 million and Whole Liquidity2 of $59.6 million, in comparison with $91.1 million and $151.6 million respectively, as of December 31, 2024.
- Income: Income for the three months ended March 31, 2025, was $7.3 million, in comparison with $5.7 million for a similar interval in 2024. Income has elevated primarily attributable to $4.0 million in product gross sales following the FDA approval of TECELRA on August 1, 2024. This was offset by a $2.4 million lower in improvement income attributable to income from Galapagos changing Genentech income and Galapagos producing comparatively decrease income as a result of collaboration being at an earlier stage of progress than the Genentech collaboration was within the first quarter of 2024.
- Analysis and improvement (R&D) bills: R&D bills for the three months ended March 31, 2025, have been $28.9 million, in comparison with $35.2 million for a similar interval in 2024. R&D bills decreased attributable to a lower within the common variety of workers engaged in R&D following the restructuring and reprioritization of actions that was introduced in November 2024 and a lower in subcontracted expenditure, offset by a lower in offsetting reimbursements receivable for R&D tax and expenditure credit.
- Promoting, normal and administrative (SG&A) bills: SG&A bills for the three months ended March 31, 2025, have been $23.3 million, in comparison with $19.7 million for the equal interval in 2024. SG&A bills elevated attributable to restructuring expenses for the restructuring program initiated within the fourth quarter of 2024 for which there was no equal within the first quarter of 2024 and a rise in accounting, authorized {and professional} charges attributable to charges regarding enterprise improvement work, offset by a lower in share-based compensation expense attributable to forfeitures arising because of the restructuring program.
- Internet loss: Internet loss attributable to holders of the Firm’s odd shares for the three months ended March 31, 2025, was a lack of $47.6 million ($0.03 per odd share), in comparison with $48.5 million ($0.03 per odd share), for the equal interval in 2024.
Going Concern
Our 2024 Annual Report on Kind 10-Okay, which the Firm filed on March 24, 2025, disclosed that there’s substantial doubt about our potential to proceed as a going concern. We’re persevering with to implement value discount measures and discover the strategic choices outlined above.
In the present day’s Webcast Particulars
A stay webcast and replay will be accessed at https://www.gowebcasting.com/14032. Name in info is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (Worldwide). Callers ought to dial in 5-10 minutes previous to the scheduled begin time and easily ask to affix the Adaptimmune name.
About Adaptimmune
Adaptimmune is a completely built-in cell remedy firm working to redefine how most cancers is handled. With its distinctive engineered T cell receptor (TCR) platform, the Firm is creating customized medicines designed to focus on and destroy difficult-to-treat stable tumor cancers and to radically enhance the affected person’s most cancers remedy expertise.
Ahead-Trying Statements
This launch comprises “forward-looking statements” inside the which means of the protected harbor provisions of Part 27A of the Securities Act and Part 21E of the Securities Change Act of 1934, as amended. Ahead-looking statements tackle our anticipated future enterprise, monetary efficiency, monetary situation, in addition to the outcomes of operations and sometimes include phrases equivalent to “anticipate” “imagine,” “count on,” “could,” “plan,” “potential,” “will,” and related expressions. Such statements are based mostly solely upon present expectations of Adaptimmune. Reliance shouldn’t be positioned on these forward-looking statements as a result of they contain sure dangers and uncertainties. Such dangers and uncertainties may trigger our precise outcomes to vary materially from these indicated by such forward-looking statements, and embody, with out limitation: the success, value and timing of our product improvement actions and medical trials and our potential to efficiently advance our TCR therapeutic candidates by way of the regulatory and commercialization processes. For an extra description of the dangers and uncertainties that would trigger our precise outcomes to vary materially from these expressed in these forward-looking statements, in addition to dangers regarding our enterprise typically, we refer you to our Annual Report on Kind 10-Okay filed with the Securities and Change Fee for the yr ended December 31, 2024, our Quarterly Experiences on Kind 10-Q, Present Experiences on Kind 8-Okay, and different filings with the Securities and Change Fee. The forward-looking statements contained on this press launch communicate solely as of the date the statements have been made and we don’t undertake any obligation to replace such forward-looking statements to mirror subsequent occasions or circumstances.
Whole Liquidity (a non-GAAP monetary measure)
Whole Liquidity (a non-GAAP monetary measure) is the full of money and money equivalents and marketable securities (available-for-sale debt securities). Every of those parts seems individually within the condensed consolidated stability sheet. The U.S. GAAP monetary measure most immediately akin to Whole Liquidity is money and money equivalents as reported within the condensed consolidated monetary statements, which reconciles to Whole Liquidity as follows (in 1000’s):
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Money and money equivalents | $ | 41,054 | $ | 91,139 | ||||
| Marketable securities – available-for-sale debt securities | 18,509 | 60,466 | ||||||
| Whole Liquidity | $ | 59,563 | $ | 151,605 | ||||
The Firm believes that the presentation of Whole Liquidity gives helpful info to traders as a result of administration opinions Whole Liquidity as a part of its evaluation of general solvency and liquidity, monetary flexibility, capital place and leverage.
Condensed Consolidated Assertion of Operations
(unaudited, in 1000’s, besides per share information)
| Three months ended | ||||||
| March 31, | ||||||
| 2025 | 2024 | |||||
| Income: | ||||||
| Product income, internet | $ | 4,048 | $ | – | ||
| Growth income | 3,237 | 5,678 | ||||
| Whole income | 7,285 | 5,678 | ||||
| Working bills: | ||||||
| Value of products offered | (879 | ) | – | |||
| Analysis and improvement | (28,857 | ) | (35,207 | ) | ||
| Promoting, normal and administrative | (23,282 | ) | (19,732 | ) | ||
| Whole working bills | (53,018 | ) | (54,939 | ) | ||
| Loss from operations | (45,733 | ) | (49,261 | ) | ||
| Curiosity revenue | 910 | 1,345 | ||||
| Curiosity expense | (1,881 | ) | – | |||
| Different revenue (expense), internet | (305 | ) | (61 | ) | ||
| Loss earlier than revenue tax expense | (47,009 | ) | (47,977 | ) | ||
| Revenue tax expense | (575 | ) | (526 | ) | ||
| Internet loss attributable to odd shareholders | $ | (47,584 | ) | $ | (48,503 | ) |
| Internet loss per odd share | ||||||
| Primary and diluted internet loss per share | $ | (0.03 | ) | $ | (0.03 | ) |
| Weighted common shares excellent: | ||||||
| Primary and diluted | 1,542,159,622 | 1,451,241,661 | ||||
Condensed Consolidated Steadiness Sheets
(unaudited, in 1000’s, besides share information)
| March 31, | December 31, | |||||
| 2025 | 2024 | |||||
| Property | ||||||
| Present property | ||||||
| Money and money equivalents | $ | 41,054 | $ | 91,139 | ||
| Marketable securities – available-for-sale debt securities (amortized value of | ||||||
| $18,512 and $60,451) internet of allowance for anticipated credit score losses of $0 and $0 | 18,509 | 60,466 | ||||
| Accounts receivable, internet of allowance for anticipated credit score losses of $0 and $0 | 4,382 | 1,454 | ||||
| Stock, internet | 11,759 | 7,320 | ||||
| Different present property and pay as you go bills | 27,294 | 27,790 | ||||
| Whole present property | 102,998 | 188,169 | ||||
| Restricted money | 1,950 | 2,067 | ||||
| Different non-current property | 377 | 629 | ||||
| Working lease right-of-use property, internet of collected amortization of $19,080 and $17,750 | 19,217 | 19,909 | ||||
| Property, plant and tools, internet of collected depreciation of $70,048 and $51,893 | 29,724 | 31,309 | ||||
| Intangible property, internet of collected amortization of $5,819 and $5,567 | 3,806 | 3,880 | ||||
| Whole property | $ | 158,072 | $ | 245,963 | ||
| Liabilities and stockholders’ fairness | ||||||
| Present liabilities | ||||||
| Accounts payable | $ | 5,701 | $ | 8,692 | ||
| Working lease liabilities, present | 4,627 | 4,709 | ||||
| Accrued bills and different present liabilities | 24,863 | 32,919 | ||||
| Restructuring provision | 3,437 | 5,911 | ||||
| Deferred income, present | 12,444 | 12,296 | ||||
| Whole present liabilities | 51,072 | 64,527 | ||||
| Working lease liabilities, non-current | 18,668 | 19,263 | ||||
| Deferred income, non-current | 95,979 | 95,815 | ||||
| Borrowings, non-current | 25,411 | 50,237 | ||||
| Different liabilities, non-current | 4,371 | 4,272 | ||||
| Whole liabilities | 195,501 | 234,114 | ||||
| Stockholders’ fairness | ||||||
| Frequent inventory – Strange shares par worth £0.001, 2,039,252,874 licensed | ||||||
| and 1,547,093,808 issued and excellent (2024: 2,039,252,874 licensed | ||||||
| and1,535,653,620 issued and excellent) | 2,099 | 2,085 | ||||
| Further paid in capital | 1,106,455 | 1,105,653 | ||||
| Amassed different complete loss | (4,412 | ) | (1,902 | ) | ||
| Amassed deficit | (1,141,571 | ) | (1,093,987 | ) | ||
| Whole stockholders’ fairness | (37,429 | ) | 11,849 | |||
| Whole liabilities and stockholders’ fairness | $ | 158,072 | $ | 245,963 |
Condensed Consolidated Money Circulation Assertion
(unaudited, in 1000’s)
| Three months ended | ||||||
| March 31, | ||||||
| 2025 | 2024 | |||||
| Money flows from working actions | ||||||
| Internet loss | $ | (47,584 | ) | $ | (48,503 | ) |
| Changes to reconcile internet loss to internet money utilized in working actions: | ||||||
| Depreciation | 2,291 | 2,771 | ||||
| Amortization | 175 | 59 | ||||
| Share-based compensation expense | 669 | 3,102 | ||||
| Unrealized international change (positive aspects)/losses | (396 | ) | 305 | |||
| Accretion of available-for-sale debt securities | (431 | ) | (23 | ) | ||
| Different | 33 | (19 | ) | |||
| Adjustments in working property and liabilities: | ||||||
| (Improve)/lower in receivables and different working property | (1,582 | ) | 15,620 | |||
| Improve in inventories | (4,426 | ) | – | |||
| Lower in payables and different present liabilities | (13,011 | ) | (7,650 | ) | ||
| Lower in noncurrent property | 281 | – | ||||
| Improve in borrowings and different non-current liabilities | 606 | – | ||||
| (Lower)/enhance in deferred income | (3,217 | ) | 2,388 | |||
| Internet money utilized in working actions | (66,592 | ) | (31,950 | ) | ||
| Money flows from investing actions | ||||||
| Acquisition of property, plant and tools | (1,203 | ) | (102 | ) | ||
| Acquisition of intangible property | – | (256 | ) | |||
| Maturity, redemption or sale of marketable securities | 58,440 | – | ||||
| Funding in marketable securities | (16,090 | ) | – | |||
| Different | 7 | – | ||||
| Internet money supplied by/(utilized in) investing actions | 41,154 | (358 | ) | |||
| Money flows from financing actions | ||||||
| Reimbursement of borrowings | (25,451 | ) | – | |||
| Proceeds from issuance of frequent inventory from choices, internet of commissions and | ||||||
| issuance prices | 122 | 29,161 | ||||
| Proceeds from train of inventory choices | 9 | 74 | ||||
| Internet money (utilized in)/supplied by financing actions | (25,320 | ) | 29,235 | |||
| Impact of foreign money change fee adjustments on money, money equivalents and restricted | ||||||
| money | 556 | (416 | ) | |||
| Internet lower in money, money equivalents and restricted money | (50,202 | ) | (3,489 | ) | ||
| Money, money equivalents and restricted money at begin of interval | 93,206 | 147,017 | ||||
| Money, money equivalents and restricted money at finish of interval | $ | 43,004 | $ | 143,528 | ||
1 Whole liquidity is a non-GAAP monetary measure, which is defined and reconciled to probably the most immediately comparable monetary measures ready in accordance with GAAP under
2 Whole liquidity is a non-GAAP monetary measure, which is defined and reconciled to probably the most immediately comparable monetary measures ready in accordance with GAAP under
To view the supply model of this press launch, please go to https://www.newsfilecorp.com/launch/251851
FAQ
What have been Adaptimmune’s (ADAP) Q1 2025 Tecelra gross sales?
Adaptimmune reported $4.0 million in Tecelra internet gross sales for Q1 2025, with full-year 2025 gross sales steering of $35-$45 million.
What’s the standing of ADAP’s lete-cel BLA submission?
Lete-cel is on observe for rolling BLA submission in late 2025, with approval anticipated in 2026. The pivotal trial met its main endpoint with 42% ORR together with 6 full responses.
What’s Adaptimmune’s present monetary place as of Q1 2025?
As of March 31, 2025, Adaptimmune had Whole Liquidity of $59.6 million, together with money and money equivalents of $41.1 million, down from $151.6 million in December 2024.
What number of Approved Therapy Facilities (ATCs) does Adaptimmune have for Tecelra?
Adaptimmune has 28 ATCs at the moment accepting referrals and is on observe to have roughly 30 ATCs open by the tip of the yr.
What was Adaptimmune’s internet loss in Q1 2025?
Adaptimmune reported a internet lack of $47.6 million ($0.03 per odd share) for Q1 2025, in comparison with $48.5 million in Q1 2024.
